Skip to content
Linkedin
RLS logo_header
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Business News
  • Conference Coverage
  • About Us
  • Choose Speciality

    Post content

    • Brain Cancer
    • Breast Cancer
      • HER2+ HRneg Breast Cancer
      • HR+ HER2neg Breast Cancer
      • TNBC
    • GI Cancers
      • Cholangiocarcinoma
      • Colorectal Cancer
      • Esophageal Cancer
      • Gastric Cancer
      • GEJ
      • GIST
      • HCC
      • Pancreatic Cancer
    • GU Cancers
      • Bladder Cancer
      • Prostate Cancer
      • Renal Cell Carcinoma
    • Gynecological Cancers
      • Cervical Cancer
      • Endometrial Cancer
      • Ovarian Cancer
    • Head & Neck Cancer
      • Nasopharyngeal Carcinoma
      • Oropharyngeal Cancer
    • Hematological Malignancies
      • CAR-Ts
    • Leukemias
      • ALL
      • AML
      • Chronic Myeloid Leukemia
      • CLL/SLL
      • CMML
    • Lung Cancer
      • Biomarker-Driven Lung Cancer
      • EGFR+ Lung Cancer
      • Non-Small Cell Lung Cancer
      • Small Cell Lung Cancer
    • Lymphomas
      • DLBCL
      • Follicular Lymphoma
      • Hodgkin’s Lymphoma
      • Mantle Cell Lymphoma
      • Non-Hodgkin’s Lymphoma
      • T-Cell Lymphoma
    • MPNs
    • Multiple Myeloma
    • Myelodysplastic Syndromes
    • Neuroendocrine Tumors
    • Sarcoma
    • Skin Cancer
    • Solid Tumors
    • Thyroid Cancer
    • Uveal Melanoma
Linkedin

Cretostimogene Monotherapy Demonstrated 75.2% Complete Response Rate in High-Risk, BCG-Unresponsive Non-Muscle Invasive Bladder Cancer

May 7, 2024

TAR-200 monotherapy shows greater than 80% complete response rate in patients with high-risk NMIBC

May 7, 2024

Data from Ph 2 registrational study of the KRAS G12C inhibitor glecirasib reported

May 7, 2024

Positive Ph 2 Preliminary Data of SLS009 in R/R AML Achieving a 100% Response Rate in Patients with ASXL1 Mutation at the Optimal Dose Level Announced

May 7, 2024

Calquence combo regimen demonstrated statistically significant and clinically meaningful PFS improvement in 1L MCL in ECHO Ph 3 trial

May 7, 2024

Ph 2 data for ERLEADA + ADT after radical prostatectomy in patients with high-risk localized prostate cancer show 100% biochemical free recurrence rate more than 2 years post-surgery

May 7, 2024

Results from ATLAS Showing Robust UGN-102 Durability of Response in New and Recurrent Low-Grade Intermediate-Risk NMIBC Announced

May 7, 2024

Positive OS Results of Anktiva Combined With Checkpoint Inhibitors in NSCLC Announced; Meeting Scheduled with FDA to Discuss Registration Path for ANKTIVA in Lung Cancer

May 1, 2024

Enhertu demonstrated statistically significant and clinically meaningful PFS improvement in HR+ve, HER2-low metastatic breast cancer following one or more lines of endocrine therapy in DESTINY-Breast06 Ph 3 trial

May 1, 2024

First Dose Level found to be Generally Well-Tolerated in Ph 1b/2 Study of Ampligen and Imfinzi Combination for Late-Stage Pancreatic Cancer

May 1, 2024

Positive Preliminary Topline Results from TACTI-003 Cohort B Announced

May 1, 2024

Imfinzi + chemo doubled OS rate at 3 years for patients with advanced biliary tract cancer in TOPAZ-1 Ph 3 trial

April 23, 2024

Columvi meets primary endpoint of OS in R/R DLBCL in Ph 3 STARGLO study

April 23, 2024

EBMT 2024: Iomab-B Overcomes High-Risk TP53 Mutation Resulting in Significant OS Improvement in R/R AML Patients

April 23, 2024

Positive Top-Line, Protocol-Planned Interim Report Data from the Study of Ampligen + Pembrolizumab for the Treatment of Recurrent Ovarian Cancer Announced

April 16, 2024

Positive Proof of Concept Data from Ph 1 Trial of ELVN-001 in CML Announced

April 16, 2024

Positive Topline Nana-val Results from Stage 1 of the NAVAL-1 Trial in Patients with R/R EBV+ PTCL Announced

April 16, 2024

Three-Year Follow-up Data in BCG-Unresponsive NMIBC Show Durable Response to Treatment with ADSTILADRIN (nadofaragene firadenovec-vncg) in 2 Patient Cohorts

April 16, 2024

Initial Data Reported from Clinical Study Evaluating ME-344 + Avastin in Relapsed Metastatic CRC Patients

April 16, 2024

Positive Preliminary PFS and Long-term ctDNA Data from Ph 2 Portion of Ongoing Ph 2/3 Study of Personalized Cancer Vaccine, GRANITE, in 1L Metastatic MSS-CRC announced

April 8, 2024

Imfinzi significantly improved OS and PFS for patients with limited-stage SCLC in ADRIATIC Ph 3 trial

April 8, 2024

Data on REZLIDHIA® (Olutasidenib) in Post-Venetoclax Patients with Mutant IDH1 AML published in Leukemia & Lymphoma

April 8, 2024

Positive Surveillance Analysis from the Randomized Ph 3 IMvigor011 Trial in MIBC announced

April 8, 2024

Positive Interim Data Announced from Randomized Ph 2 Trial of CAN-2409 in Non-Metastatic Pancreatic Cancer

April 8, 2024

FAILED TRIAL: Topline Results of Ph 2 KICKSTART Trial of Tomivosertib + Pembrolizumab in NSCLC announced

April 8, 2024
Page1 … Page11 Page12 Page13 Page14 Page15 … Page29

Onco-This-Week

  • Business News
  • Drug Approvals
  • Regulatory News
  • Trial Results
  • Trial Status
  • Conference Coverage

About Us

Sign up for OTW

Linkedin

Disclaimer: The OTW team takes care to share authentic information. In case of any discrepancies please write to newsletter@onco-this-week.com. Our website is an aggregator for open-source oncology news. The information on our website is provided without any representations or warranties. OTW is part of RLS Consultants, a global consulting and training firm focusing exclusively on the healthcare and life sciences industries. RLS is a leading provider of opportunity assessment services, utilizing its comprehensive expertise in strategic market research, forecasting, and modeling, as well as pricing and market access to facilitate commercial assessments. RLS does not have any influence on any news reported on OTW. The views and opinions expressed in this article are those of the authors and do not necessarily reflect the official policy or position of RLS. The content on our website is intended strictly for news and information purposes only and should not be treated as a substitute for medical advice, diagnosis, or treatment. News shared on OTW should not be utilized in real-world analytic products as they are based only on limited and dated open-source information.